Insider Selling: Sunesis Pharmaceuticals major shareholder Sells $2,125,599 in Stock (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) major shareholder Forest Baskett unloaded 266,700 shares of Sunesis Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $7.97, for a total transaction of $2,125,599.00. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 3.73% during mid-day trading on Friday, hitting $7.49. The stock had a trading volume of 1,903,154 shares. Sunesis Pharmaceuticals has a 1-year low of $3.84 and a 1-year high of $8.46. The stock has a 50-day moving average of $6.69 and a 200-day moving average of $6.05. The company’s market cap is $452.7 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Tuesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.
Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.